A vs UTHR
Agilent Technologies vs United Therapeutics — AI-powered side-by-side comparison
A
Agilent Technologies
65
Buy
VS
UTHR
United Therapeutics
70
Buy
| Metric | A | UTHR |
|---|
| AI Score |
65
|
70
|
| Price |
$146.09
|
$538.75
|
| P/E Ratio |
29.25×
|
17.82×
|
| ROE |
19.3%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
53.0%
|
86.1%
|
| Debt / Equity |
0.47×
|
0.00×
|
| Dividend Yield |
0.7%
|
0.0%
|
| RSI (14) |
79.0
|
66.9
|
| Beta |
1.255
|
0.58
|
| Expected Upside |
+2.0%
|
+4.6%
|
AI Committee View
Current Innellis committee reasoning for A versus UTHR.
UTHR leads by 5 points.
UTHR scores 70/100 (Buy) versus A at 65/100 (Buy).
A Committee View
83% agreement
6 analysts
The primary driver is news sentiment is positive (+0.40 across 28 articles, 14d). The main limiting factor is p/e of 29.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 20.8% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.2 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 79 is in overbought territory — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 15.0% downside vs 4.6% upside.